Caption Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Caption Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8,405	Closed	-$2.21M	–	1437
2024 Q3	$2.31M	Sell	8,405 -162,145	-95%	-$42.2M	0.04%	519
2024 Q2	$41.4M	Buy	170,550 +56,428	+49%	+$8.91M	0.64%	36
2024 Q1	$17.1M	Buy	114,122 +92,580	+430%	+$15.4M	0.26%	93
2023 Q4	$4.12M	Sell	21,542 -15,958	-43%	-$2.72M	0.06%	396
2023 Q3	$6.64M	Buy	+37,500	New	+$7.15M	0.1%	248
2023 Q2	–	Sell	-3,000	Closed	-$595K	–	1076
2023 Q1	$601K	Buy	3,000 +108	+4%	+$22.7K	0.01%	755
2022 Q4	$687K	Buy	2,892 +1,892	+189%	+$404K	0.01%	856
2022 Q3	$199K	Sell	1,000 -30,500	-97%	-$5.82M	﹤0.01%	1241
2022 Q2	$4.59M	Buy	+31,500	New	+$4.47M	0.06%	382
2021 Q4	–	Sell	-7,800	Closed	-$1.45M	–	1562
2021 Q3	$1.47M	Buy	7,800 +1,200	+18%	+$225K	0.02%	891
2021 Q2	$1.12M	Buy	+6,600	New	+$967K	0.01%	862
2021 Q1	–	Sell	-27,000	Closed	-$4.06M	–	1012
2020 Q4	$3.51M	Buy	+27,000	New	+$3.61M	0.08%	305
2018 Q4	–	Sell	-17,500	Closed	-$1.53M	–	457
2018 Q3	$1.53M	Buy	+17,500	New	+$1.76M	0.08%	279

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's ALNY Position: Q4 2024 in Review

Caption Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2024, closing a stake of 8,405 shares — an estimated $2.21M sold.

Caption Management first reported a position in ALNY in Q3 2018 and held it in 13 quarters. The position peaked at $41.4M in Q2 2024. 594 funds tracked by Wall St. Rank hold ALNY as of Q4 2024.

Caption Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Caption Management sold 8,405 Alnylam Pharmaceuticals shares in Q4 2024, an estimated $2.21M.
Caption Management first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 13 quarters.
Caption Management's Alnylam Pharmaceuticals position peaked at $41.4M in Q2 2024.
594 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2024.

Based on Caption Management's 13F filing for Q4 2024, filed 14 Feb 2025.